PPMD Community

PPMD to Host Duchenne Drug Development Roundtable During 23rd Annual Connect Conference

 
PPMD will host our annual Duchenne Drug Development Roundtable (DDDR) during the 23rd Annual Connect Conference later today. Established more than seven years ago, PPMD's DDDR is a group of committed innovators representing industry and relevant stakeholders that has the goal of accelerating the development of meaningful treatments for Duchenne through open discussion and working collaboratively in the precompetitive space to minimize duplication.

This year’s annual DDDR has never been more important or timely. There are now more than three dozen publicly and privately traded companies in Duchenne; more than a dozen therapies in late stage clinical trials; and a robust pipeline representing an array of therapeutic approaches not far behind. The Duchenne community also has crossed into the post-approval space with the accelerated approval of EXONDYS 51 in September of 2016 and the recent approval of EMFLAZA this past spring.

We appreciate each company that has come to the table to lean in even further – and we look forward to the opportunity to work together as a community to explore the innovations and opportunities that are raised through ongoing discussion and exploration. It is our hope that the DDDR will continue to assist PPMD and the Duchenne community to work together to drive forward collaborations and projects that will benefit all partners working in this space – and yield effective therapies that are accessible to all who need them.

Parent Project Muscular Dystrophy to Host Duchenne Drug Development Roundtable During 23rd Annual Connect Conference

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host their annual Duchenne Drug Development Roundtable during the organization's 23rd Annual Connect Conference being held in Chicago, Illinois

Established more than seven years ago, PPMD's Duchenne Drug Development Roundtable (DDDR) is a group of committed innovators representing industry and relevant stakeholders that has the goal of accelerating the development of meaningful treatments for Duchenne through open discussion and working collaboratively in the precompetitive space to minimize duplication.

This year's annual DDDR has never been more important or timely. There are now more than three dozen publicly and privately traded companies in Duchenne; more than a dozen therapies in late stage clinical trials; and a robust pipeline representing an array of therapeutic approaches not far behind. The Duchenne community also has crossed into the post-approval space with the accelerated approval of EXONDYS 51 in September of 2016 and the recent approval of EMFLAZA this past spring. 

But, according to PPMD Founding President and CEO, Pat Furlong, "The last two years – two years of intense product reviews for our Duchenne therapies – have provided us with new challenges and opportunities. These reviews – coupled with PPMD's policy engagement around the Duchenne community-led Draft Guidance, key provisions within 21st Century Cures, Benefit-Risk studies, and PDUFA VI discussions – have resulted in an opportunity to take what has been learned from all trial experiences and work together to become even more focused and efficient. PPMD and the leadership of our DDDR felt that this is a strategic inflection point for Duchenne; a moment to bring industry partners together to assess how these 'regulatory learnings' and new policies might best be applied back into our pipeline and into clinical trial design."

To achieve this, the DDDR Steering Committee mapped out a series of three one-day meetings that were held earlier this year. Each included leaders and innovators from outside the Duchenne space to present on opportunities to enhance our existing trial designs, tools, and infrastructure. 

The meeting series topics include:


Furlong believes that the DDDR meeting at PPMD's Connect Conference is a unique moment in the Duchenne calendar each year, providing companies and stakeholders a chance to truly connect. Says Furlong, "We appreciate each company that has come to the table to lean in even further and we look forward to the opportunity to work together as a community to explore the innovations and opportunities that are raised through ongoing discussion and exploration. It is our hope that the DDDR will continue to assist PPMD and the Duchenne community, working together to drive forward collaborations and projects that will benefit all partners working in this space and yield effective therapies that are accessible to all who need them."

PPMD's Annual Connect Conference is the largest, most comprehensive annual, international conference focused entirely on Duchenne. Each year nearly 500 families from around the world gather at PPMD's Connect Conference to learn the latest progress in the fight to end Duchenne. It is also an opportunity for families to gather for support, strength, and camaraderie. PPMD believes strongly in the power of connecting. The 2017 Connect Conference is sponsored, in part, by Elite Sponsors PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics.

Views: 290

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community

© 2017   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service